200 related articles for article (PubMed ID: 422225)
21. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
DiScipio RG
Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
[TBL] [Abstract][Full Text] [Related]
22. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
23. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
24. A new function of the activated third component of complement: binding to C5, an essential step for C5 activation.
Vogt W; Schmidt G; Von Buttlar B; Dieminger L
Immunology; 1978 Jan; 34(1):29-40. PubMed ID: 624565
[TBL] [Abstract][Full Text] [Related]
25. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
26. Incompatibility between complement components C3 and C5 of guinea-pig and man, an indication of their interaction in C5 activation by classical and alternative C5 convertases.
Von Zabern I; Nolte R; Vogt W
Scand J Immunol; 1979; 9(1):69-74. PubMed ID: 419365
[TBL] [Abstract][Full Text] [Related]
27. 'Inactivated' third component of complement (C3b-like C3; C3i) acquires C5 binding capacity and supports C5 activation upon covalent fixation to a solid surface.
Vogt W; Lühmann B; Hesse D
Complement; 1984; 1(2):87-96. PubMed ID: 6544185
[TBL] [Abstract][Full Text] [Related]
28. Factors and conditions essential for activation of the fifth component of complement and release of anaphylatoxin (C5a).
Vogt W; Schmidt G; von Buttlar B
Monogr Allergy; 1977; 12():86-9. PubMed ID: 335222
[No Abstract] [Full Text] [Related]
29. Activation of murine complement by cobra venom factor in the presence of EDTA.
Goldman JN; Bangalore S; Goldman MB
J Immunol; 1979 Nov; 123(5):2421-7. PubMed ID: 114590
[No Abstract] [Full Text] [Related]
30. Inhibition of classical C5 convertase in the complement system by factor H.
Ito S; Tamura N
Immunology; 1983 Dec; 50(4):631-5. PubMed ID: 6228516
[TBL] [Abstract][Full Text] [Related]
31. Structure/function of C5 convertases of complement.
Rawal N; Pangburn MK
Int Immunopharmacol; 2001 Mar; 1(3):415-22. PubMed ID: 11367526
[TBL] [Abstract][Full Text] [Related]
32. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
33. Generation of complement fragment C5a in milk is variable among cows.
Rainard P; Poutrel B
J Dairy Sci; 2000 May; 83(5):945-51. PubMed ID: 10821569
[TBL] [Abstract][Full Text] [Related]
34. C3 activation by a new factor B-dependent enzyme detected in culture supernatant from guinea-pig peritoneal macrophages.
Beuscher HU; Brade V
Immunology; 1986 Aug; 58(4):545-51. PubMed ID: 3089917
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of complement activation by crystalline cholesterol.
Vogt W; von Zabern I; Damerau B; Hesse D; Lühmann B; Nolte R
Mol Immunol; 1985 Feb; 22(2):101-6. PubMed ID: 3156272
[TBL] [Abstract][Full Text] [Related]
36. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
[TBL] [Abstract][Full Text] [Related]
37. Identification of functionally relevant determinants on the complement component C3 with monoclonal antibodies.
Burger R; Deubel U; Hadding U; Bitter-Suermann D
J Immunol; 1982 Nov; 129(5):2042-50. PubMed ID: 6181157
[No Abstract] [Full Text] [Related]
38. EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5.
Orth D; Ehrlenbach S; Brockmeyer J; Khan AB; Huber G; Karch H; Sarg B; Lindner H; Würzner R
Infect Immun; 2010 Oct; 78(10):4294-301. PubMed ID: 20643852
[TBL] [Abstract][Full Text] [Related]
39. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
Front Immunol; 2018; 9():1691. PubMed ID: 30083158
[TBL] [Abstract][Full Text] [Related]
40. Magnetic bead based assays for complement component C5.
DiScipio RG; Schraufstatter IU
J Immunol Methods; 2017 Nov; 450():50-57. PubMed ID: 28757372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
